Company intelligence / Profile preview

Merry Life Biomedical Co., Ltd.

Ownership: Private
Development stage: Other

Overview

Merry Life Biomedical focuses on developing new small molecule drugs for neurodegenerative diseases, particularly Alzheimer's disease. Its lead candidate TML‑6 targets multiple pathways implicated in Alzheimer’s and has reached Phase 1 clinical trials. Another candidate, NP‑106 targeting APP, appears to be in a preclinical or pending stage. The company positions itself as addressing the growing societal burden of dementia and Alzheimer’s with innovative therapeutics but no late-stage or commercialized products are reported as of March 2025.

Therapeutic areas: Neurology
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

1 asset

TML-6

Beyond the preview

Go deeper on Merry Life Biomedical Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Merry Life Biomedical Co., Ltd..

Explore the full profile